BillionToOne, Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Prenatal at $277.1 million, 91% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
|---|---|---|
| Revenue |
437
|
305
|
| Prenatal |
381
+62.7%
share 87.2%
|
277
share 90.8%
|
| Oncology |
51
+199.1%
share 11.6%
|
25
share 8.2%
|
| Clinical Trial Support And Other Services |
5
+70.5%
share 1.2%
|
3
share 1.0%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BLLN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2070849
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- CareDx, Inc. CDNA
Source: SEC EDGAR filings. This is company-reported data, not investment advice.